The Delhi High Court has permitted Natco Pharma to launch its affordable generic version of risdiplam, a crucial drug for spinal muscular atrophy. This decision overturns a previous stay, allowing Natco to offer the medication at a significantly lower price than Swiss multinational Roche's imported Evrysdi. Roche expressed disappointment, emphasizing the importance of patent protection for innovation.